Xu Peiyi, Zhang Qiuyan, Zhai Jing, Chen Pu, Deng Xueting, Miao Lin, Zhang Xiuhua
Department of Gastroenterology, Second Affiliated Hospital, Nanjing Medical University, 121 Jiangjiayuan Road, Gulou District, Nanjing, Jiangsu, China.
Discov Oncol. 2024 Dec 23;15(1):830. doi: 10.1007/s12672-024-01697-4.
ZBTB11 is a putative transcription factor with an N-terminal BTB domain and tandem C-terminal zinc finger motifs. Recent studies have suggested a potential role for ZBTB11 in tumorigenesis. However, the biological significance of ZBTB11 in different cancer types remains uncertain.
The expression levels, prognostic values, genetic mutations, and DNA promoter methylation of ZBTB11 across tumor types were explored via various online websites and databases, including TIMER2.0, GEPIA2, cBioPortal, UALCAN, GSCA, CancerSEA, and others. Additionally, a competing lncRNA-miRNA network of ZBTB11 was constructed, and its interaction with chemicals and genes was investigated.
Our findings revealed that ZBTB11 was aberrantly expressed in a multitude of tumor types and exhibited variability across various tumor stages. A survival analysis revealed that ZBTB11 predicted a poor prognosis in BRCA, KIRP, LIHC, PCPG, PRAD, SARC, UCEC, and a good prognosis in CHOL, ESCA, GBM, KIRC, and READ. We also found that the most frequent genetic alterations type of ZBTB11 was mutation, and the DNA methylation level of ZBTB11 decreased in various cancers. Furthermore, ZBTB11 expression correlated with immune cells infiltration and genetic markers of immunodulators in cancers. Moreover, the results of single-cell sequencing demonstrated that ZBTB11 could regulate several tumor biological behaviors, including apoptosis, DNA damage, and angiogenesis. A lncRNA-miRNA network regulating ZBTB11 expression in tumor development and progression was constructed. It is of particular significance that ZBTB11 demonstrated a correlation with the CTRP and GDSC drug sensitivity, and that it served as a mediator between chemicals and cancers.
These findings demonstrate that ZBTB11 is associated with multiple tumor types and disease prognosis. ZBTB11 may represent a potential key biomarker and therapeutic target in cancers.
ZBTB11是一种假定的转录因子，具有N端BTB结构域和串联的C端锌指基序。最近的研究表明ZBTB11在肿瘤发生中具有潜在作用。然而，ZBTB11在不同癌症类型中的生物学意义仍不确定。
通过各种在线网站和数据库，包括TIMER2.0、GEPIA2、cBioPortal、UALCAN、GSCA、CancerSEA等，探索ZBTB11在不同肿瘤类型中的表达水平、预后价值、基因突变和DNA启动子甲基化情况。此外，构建了ZBTB11的竞争性lncRNA-miRNA网络，并研究了其与化学物质和基因的相互作用。
我们的研究结果显示，ZBTB11在多种肿瘤类型中异常表达，且在不同肿瘤阶段表现出变异性。生存分析表明，ZBTB11在BRCA、KIRP、LIHC、PCPG、PRAD、SARC、UCEC中预示预后不良，而在CHOL、ESCA、GBM、KIRC和READ中预示预后良好。我们还发现，ZBTB11最常见的基因改变类型是突变，并且ZBTB11的DNA甲基化水平在各种癌症中降低。此外，ZBTB11表达与癌症中的免疫细胞浸润和免疫调节剂的遗传标记相关。而且，单细胞测序结果表明ZBTB11可以调节多种肿瘤生物学行为，包括细胞凋亡、DNA损伤和血管生成。构建了一个在肿瘤发生发展中调节ZBTB11表达的lncRNA-miRNA网络。特别重要的是，ZBTB11与CTRP和GDSC药物敏感性相关，并且它在化学物质和癌症之间起介导作用。
这些发现表明ZBTB11与多种肿瘤类型和疾病预后相关。ZBTB11可能是癌症中潜在的关键生物标志物和治疗靶点。
